Dynamic Technology Lab Private Ltd acquired a new stake in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 8,547 shares of the medical equipment provider’s stock, valued at approximately $932,000.
Several other hedge funds and other institutional investors also recently bought and sold shares of ZBH. Bedel Financial Consulting Inc. acquired a new position in shares of Zimmer Biomet during the 1st quarter valued at about $111,000. Summit Trail Advisors LLC increased its stake in shares of Zimmer Biomet by 8,836.9% during the 1st quarter. Summit Trail Advisors LLC now owns 127,887 shares of the medical equipment provider’s stock valued at $128,000 after acquiring an additional 126,456 shares during the last quarter. Massey Quick Simon & CO. LLC increased its stake in shares of Zimmer Biomet by 100.0% during the 1st quarter. Massey Quick Simon & CO. LLC now owns 1,200 shares of the medical equipment provider’s stock valued at $131,000 after acquiring an additional 600 shares during the last quarter. We Are One Seven LLC acquired a new position in shares of Zimmer Biomet during the 4th quarter valued at about $137,000. Finally, Adviser Investments LLC acquired a new position in shares of Zimmer Biomet during the 1st quarter valued at about $144,000. 87.38% of the stock is owned by institutional investors.
A number of analysts recently issued reports on ZBH shares. Evercore ISI started coverage on shares of Zimmer Biomet in a research report on Monday, April 2nd. They set an “in-line” rating and a $115.00 target price for the company. Robert W. Baird downgraded shares of Zimmer Biomet from an “outperform” rating to a “neutral” rating in a research report on Friday, March 23rd. Citigroup dropped their target price on shares of Zimmer Biomet from $132.00 to $121.00 and set a “neutral” rating for the company in a research report on Tuesday, February 27th. Canaccord Genuity reissued a “hold” rating and set a $121.00 target price on shares of Zimmer Biomet in a research report on Thursday, April 12th. Finally, Oppenheimer started coverage on shares of Zimmer Biomet in a research report on Thursday, March 15th. They set an “outperform” rating and a $135.00 target price for the company. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. Zimmer Biomet has a consensus rating of “Buy” and a consensus price target of $137.71.
NYSE ZBH opened at $112.56 on Wednesday. The company has a market capitalization of $22.72 billion, a price-to-earnings ratio of 14.02, a P/E/G ratio of 2.18 and a beta of 1.14. Zimmer Biomet Holdings Inc has a fifty-two week low of $104.28 and a fifty-two week high of $133.49. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.69 and a quick ratio of 1.07.
Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Thursday, April 26th. The medical equipment provider reported $1.91 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.89 by $0.02. The firm had revenue of $2.02 billion during the quarter, compared to analysts’ expectations of $1.98 billion. Zimmer Biomet had a return on equity of 14.36% and a net margin of 21.81%. Zimmer Biomet’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.13 EPS. sell-side analysts forecast that Zimmer Biomet Holdings Inc will post 7.67 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 31st. Shareholders of record on Friday, June 29th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.85%. The ex-dividend date is Thursday, June 28th. Zimmer Biomet’s dividend payout ratio is presently 11.96%.
In other news, VP Tony W. Collins sold 1,330 shares of the stock in a transaction that occurred on Monday, April 30th. The stock was sold at an average price of $116.73, for a total transaction of $155,250.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Katarzyna Mazur-Hofsaess sold 8,765 shares of the stock in a transaction that occurred on Tuesday, May 22nd. The shares were sold at an average price of $113.61, for a total value of $995,791.65. Following the transaction, the insider now owns 25,447 shares of the company’s stock, valued at $2,891,033.67. The disclosure for this sale can be found here. 0.71% of the stock is owned by corporate insiders.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.